Zacks Investment Research on MSN
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...
Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them ...
Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...
InvestorsHub on MSN
Eli Lilly Raises Full-Year Guidance on Soaring Demand for Weight-Loss Drugs
Eli Lilly (NYSE:LLY) raised its full-year outlook on Thursday after delivering third-quarter results that handily beat ...
Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro, launched earlier this year.
On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...
The decision to discontinue production was driven by business considerations rather than concerns about the product’s safety or effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback